GENMAB på Børsen Play efter Q3
-
"Genmab opjusterer forventningerne".
http://play.borsen.dk/social/5639afd1725ed7540a0c6296
Nordea: "Der er forsat potentiale i Genmab".
http://play.borsen.dk/social/5639b020725ed7540a0c62ae
Genmabchef: "Vi vil gå over i historien med Daratumumab".
http://play.borsen.dk/social/5639b7e0725ed7540a0c62fc
Storinvestor: "Prisen på Genmab er urealistisk lav".
http://play.borsen.dk/social/5639ba91725ed7540a0c6323
Kjærgaard: "Skynd dig at hoppe på Genmabtoget".
http://play.borsen.dk/social/5639ec95725ed7540a0c641f
Redaktør: "Det kan være svært at se, hvad der kan få Genmab-aktien ned".
http://play.borsen.dk/social/563a0031725ed7540a0c6465
Nordea: "Risikoen og potentialet er stor i Genmab".
-
Fornuftige overvejelser omkring Fingerprint Cards prissætning fra Christian Kjærgaard:
-
Teknisk analyse på Genmab på Børsen Play:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind